Our Services
Medical Information
Helpful Resources
Published on: 7/21/2026
Perimenopause and Ozempic can cause double fatigue by combining hormonal fluctuations, sleep disturbances, and appetite suppression that reduces calorie and nutrient intake. Key strategies to restore energy include:
Because fatigue can stem from many overlapping causes—hormonal, nutritional, or medication-related—guessing the source can delay real relief. A free, instant, online symptom check can help you pinpoint likely contributors and clarify your next steps, whether that's lab work, a dose review, or a specialist visit. It takes only a few minutes and gives you personalized guidance you can act on today.
Reviewed for medical accuracy: 07/21/2026
Feeling wiped out despite your best efforts? You're not alone. Many women experience double fatigue when perimenopause joins forces with medications like Ozempic. Understanding why these energy drains happen—and what you can do about them—can help you reclaim your vitality.
Perimenopause is the transitional phase before menopause, typically starting in your 40s but sometimes earlier. Hormones—especially estrogen and progesterone—fluctuate unpredictably, leading to:
All these shifts combine to slow you down. If you're wondering "Is this just aging?" know that perimenopause fatigue is a real, treatable condition.
Ozempic (semaglutide) is a GLP-1 receptor agonist prescribed for type 2 diabetes and, at lower doses, for weight management. It works by:
While these effects help with blood sugar control and weight loss, they can also contribute to low energy:
The result? Ozempic fatigue layering on top of perimenopausal exhaustion.
When perimenopause and Ozempic team up, you might experience:
Hormonal dips from perimenopause already disrupt your energy reserves. Adding Ozempic's appetite-suppressing effects can leave you with insufficient calories and nutrients to power daily life.
You don't have to accept "just feeling tired." Try a multi-pronged approach:
Some symptoms warrant urgent medical attention. Contact your doctor or go to the emergency room if you experience:
Always let your healthcare provider know about any new, worsening or life-threatening symptoms.
Not sure if your fatigue is mostly perimenopause, Ozempic-related or something else? Try Ubie's free AI-powered Menopause Symptom Checker to help identify your most troubling symptoms and get personalized insights in just a few minutes. This can help you prepare for a focused, productive discussion with your doctor.
Double fatigue from perimenopause and Ozempic can feel overwhelming, but it's manageable. By combining nutritional tweaks, lifestyle adjustments, medical evaluation and mindful self-care, you can regain your energy and feel like yourself again. If you ever feel that your symptoms are life-threatening or severely impacting daily life, don't hesitate—reach out to a healthcare professional right away.
Remember: you deserve energy, vitality and relief. A tailored plan with your doctor's guidance is the best path forward.
Speak to a doctor about any serious or persistent symptoms to ensure you get the care you need.
(References)
* Thurston, R. C., Chang, Y., Janssen, I., & Wiseman, A. L. (2020). Fatigue and sleep disturbances in midlife women: A scoping review. *Maturitas*, *139*, 19-30. DOI: 10.1016/j.maturitas.2020.06.009. PMID: 32773179.
* Zhao, D., Zhang, Y., Han, S., Zhang, J., & Li, R. (2022). Systematic review and meta-analysis of fatigue and somnolence associated with GLP-1 receptor agonists. *Endocrine*, *78*(1), 16-25. DOI: 10.1007/s12020-022-03120-x. PMID: 35915152.
* Santoro, N., Sessa, D., Napolitano, V., Di Somma, C., Pivonello, C., Colao, A., & Pivonello, R. (2023). Management of obesity in menopausal women. *Expert Review of Endocrinology & Metabolism*, *18*(4), 303-317. DOI: 10.1080/17446651.2023.2244199. PMID: 37553896.
* Lee, J., Lee, J., Lim, H., & Park, M. (2021). Current understanding and management of fatigue in perimenopausal women. *Korean Journal of Women Health Nursing*, *27*(4), 329-338. DOI: 10.4069/kjwhn.2021.11.23. PMID: 34907998.
* Nauck, M. A., Meier, J. J., & Nauck, M. A. (2021). Safety and tolerability of glucagon-like peptide-1 receptor agonists. *Frontiers in Endocrinology*, *12*, 670222. DOI: 10.3389/fendo.2021.670222. PMID: 34093220.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.